Wan Ling Tan

1.0k total citations
22 papers, 407 citations indexed

About

Wan Ling Tan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Wan Ling Tan has authored 22 papers receiving a total of 407 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 4 papers in Surgery. Recurrent topics in Wan Ling Tan's work include Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Gastric Cancer Management and Outcomes (6 papers). Wan Ling Tan is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Gastric Cancer Management and Outcomes (6 papers). Wan Ling Tan collaborates with scholars based in Singapore, United States and Taiwan. Wan Ling Tan's co-authors include Brian K. P. Goh, Andrew X. Zhu, Wai Meng David Tai, Su Pin Choo, Amit Jain, Wan‐Teck Lim, Quan Sing Ng, Balram Chowbay, Ravindran Kanesvaran and Chee‐Keong Toh and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Wan Ling Tan

20 papers receiving 405 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wan Ling Tan Singapore 8 152 149 144 92 85 22 407
Jin Gu China 11 85 0.6× 172 1.2× 80 0.6× 93 1.0× 74 0.9× 36 412
Hitomi Suzuki Japan 9 99 0.7× 111 0.7× 106 0.7× 42 0.5× 77 0.9× 43 459
Wen‐Ping Lin China 13 90 0.6× 196 1.3× 185 1.3× 91 1.0× 57 0.7× 30 388
Norifumi Iseda Japan 13 159 1.0× 171 1.1× 104 0.7× 180 2.0× 56 0.7× 54 498
Xihui Ying China 9 95 0.6× 102 0.7× 188 1.3× 40 0.4× 53 0.6× 18 397
Go Ohira Japan 11 74 0.5× 255 1.7× 107 0.7× 61 0.7× 67 0.8× 53 413
Loretta D’Onofrio Italy 8 80 0.5× 137 0.9× 93 0.6× 77 0.8× 46 0.5× 18 299
Kongying Lin China 12 79 0.5× 96 0.6× 206 1.4× 186 2.0× 123 1.4× 48 466
Zebin Chen China 12 83 0.5× 118 0.8× 259 1.8× 81 0.9× 77 0.9× 28 485
Jianxing Zeng China 11 44 0.3× 132 0.9× 131 0.9× 74 0.8× 89 1.0× 37 372

Countries citing papers authored by Wan Ling Tan

Since Specialization
Citations

This map shows the geographic impact of Wan Ling Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wan Ling Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wan Ling Tan more than expected).

Fields of papers citing papers by Wan Ling Tan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wan Ling Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wan Ling Tan. The network helps show where Wan Ling Tan may publish in the future.

Co-authorship network of co-authors of Wan Ling Tan

This figure shows the co-authorship network connecting the top 25 collaborators of Wan Ling Tan. A scholar is included among the top collaborators of Wan Ling Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wan Ling Tan. Wan Ling Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tan, Wan Ling, Sze Huey Tan, Daniel S.W. Tan, et al.. (2023). EP12.01-31 Updated First-line Osimertinib in Asian patients with Advanced EGFR-mutated Lung Cancer. Journal of Thoracic Oncology. 18(11). S652–S653.
2.
Saw, Stephanie P.L., Gek San Tan, Aaron C. Tan, et al.. (2023). Brief Report: Droplet Digital Polymerase Chain Reaction Versus Plasma Next-Generation Sequencing in Detecting Clearance of Plasma EGFR Mutations and Carcinoembryonic Antigen Levels as a Surrogate Measure. JTO Clinical and Research Reports. 4(12). 100599–100599. 2 indexed citations
3.
4.
Li, Xiuting, Mohesh Moothanchery, Wan Ling Tan, et al.. (2022). Multispectral raster-scanning optoacoustic mesoscopy differentiate lesional from non-lesional atopic dermatitis skin using structural and functional imaging markers. Photoacoustics. 28. 100399–100399. 14 indexed citations
5.
Tan, Wan Ling, Sze Huey Tan, Daniel Shao-Weng Tan, et al.. (2021). P76.46 First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer. Journal of Thoracic Oncology. 16(3). S607–S607. 1 indexed citations
6.
Ng, Quan Sing, Daniel S.W. Tan, Wan Ling Tan, et al.. (2020). 266O Combination ipilimumab and nivolumab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Updated efficacy and safety analysis of NCT03097939. Annals of Oncology. 31. S1347–S1347. 7 indexed citations
7.
Lim, Wan‐Teck, Quan Sing Ng, Ruey‐Long Hong, et al.. (2020). Abstract CT203: A phase II trial of ipilimumab in combination with nivolumab in EBV-associated advanced nasopharyngeal carcinoma (NCT03097939). Cancer Research. 80(16_Supplement). CT203–CT203. 2 indexed citations
8.
Tan, Wan Ling, Kevin Lee Min Chua, Chia‐Chi Lin, et al.. (2019). Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. Journal of Thoracic Oncology. 15(3). 324–343. 40 indexed citations
9.
10.
Tan, Wan Ling, et al.. (2018). P1.16-07 Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients with High PD-L1 Expression in Singapore. Journal of Thoracic Oncology. 13(10). S630–S630. 2 indexed citations
11.
Marvalim, Charlie, Wan‐Teck Lim, Ravindran Kanesvaran, et al.. (2017). Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients. Pharmacogenetics and Genomics. 27(3). 120–123. 3 indexed citations
12.
Shi, Jun, Jamie Mong, Tan Min Chin, et al.. (2017). EGFR mutation detection in plasma cell-free DNA correlates with clinical outcomes in non-small cell lung cancer. Annals of Oncology. 28. v476–v477. 1 indexed citations
13.
14.
Tan, Wan Ling, et al.. (2016). 139PD: Lifetime incidence of brain metastases (BM) in EGFR-mutant (M+) lung cancer treated with first-line EGFR TKIs. Journal of Thoracic Oncology. 11(4). S117–S117. 3 indexed citations
15.
Tan, Eng Huat, Wan‐Teck Lim, Ravindran Kanesvaran, et al.. (2016). EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. Journal of Thoracic Oncology. 12(3). 529–538. 61 indexed citations
16.
17.
Choo, Su Pin, Wan Ling Tan, Brian K. P. Goh, Wai Meng David Tai, & Andrew X. Zhu. (2016). Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 122(22). 3430–3446. 210 indexed citations
18.
19.
Stein, Mark N., et al.. (2010). ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 28(15_suppl). 4556–4556. 8 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jin Gu Breakdown of academic impact, for papers by Hitomi Suzuki Breakdown of academic impact, for papers by Wen‐Ping Lin Breakdown of academic impact, for papers by Norifumi Iseda Breakdown of academic impact, for papers by Xihui Ying Breakdown of academic impact, for papers by Go Ohira Breakdown of academic impact, for papers by Loretta D’Onofrio Breakdown of academic impact, for papers by Kongying Lin Breakdown of academic impact, for papers by Zebin Chen Breakdown of academic impact, for papers by Jianxing Zeng
Rankless by CCL
2026